Tonix Pharmaceuticals posting a volatile trading session after posting data from its cyclobenzaprine study at Seattle symposium

|About: Tonix Pharmaceuticals Holdi... (TNXP)|By:, SA News Editor

Tonix Pharmaceuticals (TNXP -4.8%) reverses early gains to trade lower today, despite posting results from its nonclinical studies of cyclobenzaprine, the active ingredient of its lead candidate, TNX-102 sublingual tablet, at the International Pain Society's Ninth World Congress on Myofascial Pain Syndrome and Fibromyalgia Syndrome in Seattle, Washington.

The company notes that cyclobenzaprine exerts multiple effects on serotonergic and adrenergic neurotransmission, and that TNX-102 SL exerts pharmacological effects distinct from those exerted by products approved by the Food and Drug Administration for the management of fibromyalgia and PTSD.